ArticleThe American journal of pathology1998
MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule).
Article in The American journal of pathology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 136 citations in OpenAlex.
- Osteomacs promote maintenance of murine hematopoiesis through megakaryocyte-induced upregulation of Embigin and CD166.Stem cell reports · 2024Article
- Nectins and Nectin-like molecules drive vascular development and barrier function.Angiogenesis · 2023Review
- Alcam-a and Pdgfr-α are essential for the development of sclerotome-derived stromal cells that support hematopoiesis.Nature communications · 2023Article
- Comparative gene expression analysis of stemness between periodontal ligament and umbilical cord tissues in humans.Journal of dental sciences · 2023Article
- Up-regulation of pro-angiogenic molecules and events does not relate with an angiogenic switch in metastatic osteosarcoma cells but to cell survival features.Apoptosis : an international journal on programmed cell death · 2021Article
- Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead.Cells · 2021Review
- CD166 promotes the cancer stem-like properties of primary epithelial ovarian cancer cells.BMB reports · 2020Article
- ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium.Neuro-oncology · 2020Article
- Importance of activated leukocyte cell adhesion molecule (ALCAM) in prostate cancer progression and metastatic dissemination.Oncotarget · 2019Article
- Roles of microRNAs and RNA-Binding Proteins in the Regulation of Colorectal Cancer Stem Cells.Cancers · 2017Review
- Cell Adhesion Molecule CD166/ALCAM Functions Within the Crypt to Orchestrate Murine Intestinal Stem Cell Homeostasis.Cellular and molecular gastroenterology and hepatology · 2017Article
- Extracellular protonation modulates cell-cell interaction mechanics and tissue invasion in human melanoma cells.Scientific reports · 2017Article
- MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding.Clinical & experimental metastasis · 2016Article
- Article
- Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.Diagnostic pathology · 2015Article
- ALCAM is indirectly modulated by miR-125b in MCF7 cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Functional role of endothelial adhesion molecules in the early stages of brain metastasis.Neuro-oncology · 2014Article
- The role of novel and known extracellular matrix and adhesion molecules in the homeostatic and regenerative bone marrow microenvironment.Cell adhesion & migration · 2014Review
- Alcam regulates long-term hematopoietic stem cell engraftment and self-renewal.Stem cells (Dayton, Ohio) · 2013Article
- HMMC-1, a human monoclonal antibody to fucosylated core 1 O-glycan, suppresses growth of uterine endometrial cancer cells.Cancer science · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
From a differential mRNA display comparing a non- and a highly metastasizing human melanoma cell line, we isolated and characterized memD. memD is preferentially expressed in the highly metastasizing melanoma cell lines of a larger panel. The encoded protein, MEMD, is identical to activated leukocyte cell adhesion molecule (ALCAM), a recently identified ligand of CD6. ALCAM is involved in homophylic (ALCAM-ALCAM) and heterophylic (ALCAM-CD6) cell adhesion interactions. We have studied MEMD/ALCAM cell-cell interactions between human melanoma cells. The expression of this cell adhesion molecule not only correlates with enhanced metastatic properties and with aggregational behavior of human melanoma cells as tested by FACS analysis, but transfection experiments also make clear that MEMD/ALCAM expression is essential for cell-cell interaction of the investigated human melanoma cells. As the melanoma cell lines analyzed are all CD6 negative, these results strongly suggest that MEMD/ALCAM is an adhesion molecule mediating homophylic clustering of melanoma cells. MEMD/ALCAM expression is not restricted to subsets of leukocytes and melanoma cells, it can also be found in healthy organs and in several other malignant tumor cell lines. Besides, MEMD/ALCAM is also expressed in cultured endothelial cells, pericytes and melanocytes, in xenografts derived from the radial and vertical growth phase and in 4 of 13 melanoma metastasis lesions. The potential role is discussed of MEMD/ALCAM mediated cell-cell interactions in migration of mobile cells (ie, activated leukocytes, metastasizing tumor cells) through tissues.
Indexed as
Identifiers
9502422PMC1858405W2237585893What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.